HDT Bio

Executive Summary

HDT Bio is a clinical-stage private biotechnology company headquartered in Seattle, Washington, focused on developing novel therapies and vaccines for cancer and infectious diseases. Founded in 2017, the company leverages its proprietary LION™ delivery platform, which is designed to enhance the safety, potency, durability, and manufacturability of nucleic acid-based products. HDT Bio is currently advancing its pipeline through Phase 1 clinical trials, with a primary emphasis on oncology and infectious disease indications. The LION platform differentiates itself through its ability to stimulate robust immune responses with reduced reactogenicity compared to conventional lipid nanoparticle systems, potentially enabling broader therapeutic applications and manufacturing scalability. As a private entity, HDT Bio has not disclosed total funding or valuation, but its platform has attracted attention for its versatility in both cancer immunotherapy and vaccine development. The company's early-stage status implies significant uncertainty, yet its technology holds promise for addressing unmet medical needs across multiple indications.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 Data Readout for Lead Oncology Candidate55% success
• Q4 2026IND Submission for Infectious Disease Vaccine60% success
• TBDStrategic Partnership or Licensing Deal for LION Platform40% success